Garth Cumberlidge is now serving in a new board position at Eyevensys SAS

Mar 21, 2017
Board and Executive Moves
Background Information
Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.